Basel Karzoun - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Basel Karzoun

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Pharmaceutics|June 27, 2025

Formulation and Characterization of Bone-Targeting Vancomycin-Loaded LiposomesBasel Karzoun, Wala'a Albenayan, Shilpa Raut, et al.

International Journal of Molecular Sciences|June 26, 2025

Breaking the Triad: Immune Tolerance Induction Without Antigen Co-Presentation via Tim Agonist for the Treatment of Autoimmune DiseasesBasel Karzoun, Abdulraouf Ramadan, Saleh Allababidi, et al.

Pharmaceutics|November 27, 2025

LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis ModelsAnas M Fathallah, Abdulraouf Ramadan, Basel Karzoun, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Pharmaceutics|June 27, 2025

Formulation and Characterization of Bone-Targeting Vancomycin-Loaded LiposomesBasel Karzoun, Wala'a Albenayan, Shilpa Raut, et al.

International Journal of Molecular Sciences|June 26, 2025

Breaking the Triad: Immune Tolerance Induction Without Antigen Co-Presentation via Tim Agonist for the Treatment of Autoimmune DiseasesBasel Karzoun, Abdulraouf Ramadan, Saleh Allababidi, et al.

Pharmaceutics|November 27, 2025

LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis ModelsAnas M Fathallah, Abdulraouf Ramadan, Basel Karzoun, et al.

Pageof 1